Skip to main navigation Skip to search Skip to main content

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non–small cell lung cancer

  • Vassiliki A. Papadimitrakopoulou
  • , Ji Youn Han
  • , Myung Ju Ahn
  • , Suresh S. Ramalingam
  • , Angelo Delmonte
  • , Te Chun Hsia
  • , Janessa Laskin
  • , Sang We Kim
  • , Yong He
  • , Chun Ming Tsai
  • , Toyoaki Hida
  • , Makoto Maemondo
  • , Terufumi Kato
  • , Suzanne Jenkins
  • , Sabina Patel
  • , Xiangning Huang
  • , Gianluca Laus
  • , Aleksandra Markovets
  • , Kenneth S. Thress
  • , Yi Long Wu
  • Tony Mok
  • University of Texas MD Anderson Cancer Center
  • National Cancer Center
  • Emory University
  • IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
  • China Medical University Taichung
  • Provincial Health Services Authority
  • University of Ulsan
  • Daping Hospital, the Third Military Medical University
  • Veterans General Hospital-Taipei
  • Aichi Cancer Center Hospital and Research Institute
  • Iwate Medical University
  • Kanagawa Cancer Center Research Institute
  • AstraZeneca
  • Guangdong Academy of Medical Sciences
  • Chinese University of Hong Kong

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non–small cell lung cancer'. Together they form a unique fingerprint.
Sort by

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science